search button
Open Access

Dual inhibition of MET and SRC kinase activity as a combined targeting strategy for colon cancer

  • Authors:
    • Na Song
    • Xiujuan Qu
    • Shizhou Liu
    • Simeng Zhang
    • Jing Liu
    • Jinglei Qu
    • Huachuan Zheng
    • Yunpeng Liu
    • Xiaofang Che

  • View Affiliations

  • Published online on: June 27, 2017     https://doi.org/10.3892/etm.2017.4692
  • Pages: 1357-1366

  • Copyright: © Song et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Hepatocyte growth factor (HGF)/MET signaling is implicated in the development of colorectal cancer (CRC) and possesses therapeutic value for various types of cancer. However, inhibition of MET alone has been demonstrated to have limited efficacy. The present study examined the combined inhibition of MET and SRC kinase activity in colon cancer cells. Furthermore, the role of the HGF/MET pathway in ligand‑dependent and ‑independent activation was demonstrated. The single inhibition of MET by knockdown small interfering RNA or inhibitor indicated a limited anti‑viability effects without inhibiting the basal phosphorylation levels of SRC, protein kinase B (AKT) or extracellular signal‑regulated kinase (ERK). In view of the strong association between MET and SRC identified by direct regulation, growth factor‑induced MET activation was suppressed by pretreatment with the SRC inhibitor, dasatinib, and downstream phosphorylation of AKT and ERK partially decreased, which suggested that SRC activation was essential for ligand‑dependent and ‑independent activation of MET. Considering that both the activation of MET and SRC was required in ligand‑dependent and ‑independent MET activation, the antitumor effect of concurrent inhibition of MET and SRC was examined, and it was demonstrated that combination treatment exerted increased viability inhibition and apoptosis enhancement in mutant and wild type RAS colon cancer cells. Therefore, combinational inhibition of MET and SRC may be a promising strategy for the treatment of CRC.
View Figures
View References

Related Articles

Journal Cover

August-2017
Volume 14 Issue 2

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.4
  • Ranked Medicine Research and Experimental
    (total number of cites)
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Song N, Qu X, Liu S, Zhang S, Liu J, Qu J, Zheng H, Liu Y and Che X: Dual inhibition of MET and SRC kinase activity as a combined targeting strategy for colon cancer. Exp Ther Med 14: 1357-1366, 2017.
APA
Song, N., Qu, X., Liu, S., Zhang, S., Liu, J., Qu, J. ... Che, X. (2017). Dual inhibition of MET and SRC kinase activity as a combined targeting strategy for colon cancer. Experimental and Therapeutic Medicine, 14, 1357-1366. https://doi.org/10.3892/etm.2017.4692
MLA
Song, N., Qu, X., Liu, S., Zhang, S., Liu, J., Qu, J., Zheng, H., Liu, Y., Che, X."Dual inhibition of MET and SRC kinase activity as a combined targeting strategy for colon cancer". Experimental and Therapeutic Medicine 14.2 (2017): 1357-1366.
Chicago
Song, N., Qu, X., Liu, S., Zhang, S., Liu, J., Qu, J., Zheng, H., Liu, Y., Che, X."Dual inhibition of MET and SRC kinase activity as a combined targeting strategy for colon cancer". Experimental and Therapeutic Medicine 14, no. 2 (2017): 1357-1366. https://doi.org/10.3892/etm.2017.4692